FU Xiangjun, HUANG Li, GUO Li, et al. Clinical Application of Polymyxin B Sulfate for Injection in Hainan General Hospital. [J]. 21(8):991-994(2021)
DOI:
FU Xiangjun, HUANG Li, GUO Li, et al. Clinical Application of Polymyxin B Sulfate for Injection in Hainan General Hospital. [J]. 21(8):991-994(2021) DOI: 10.14009/j.issn.1672-2124.2021.08.022.
Clinical Application of Polymyxin B Sulfate for Injection in Hainan General Hospital
OBJECTIVE: To investigate the clinical application of polymyxin B sulfate for injection in Hainan General Hospital( hereinafter referred to as “our hospital”)
so as to provide reference for the rational use of polymyxin B sulfate for injection. METHODS: Patients admitted into our hospital from Jan. 1 st
2018 to Mar. 15 th
2021 and received polymyxin B sulfate for injection were selected as the research objectives. The basic information
results of pathogen examination
usage and dosage of polymyxtin B sulfate for injection
drug combination
treatment outcome and adverse drug reactions were analyzed retrospectively. RESULTS: A total of 51 patients were enrolled in the study
including 34 males( 66. 67%) and 17 females( 33. 33%)
with an average age of( 61. 31 ± 17. 98) years. Totally137 pathogenic positive specimens were detected
and 115 strains of Gram-negative bacteria were detected
the detection rate of Gram-negative bacteria was 83. 94%
among which 55 strains( 47. 83%) of extensively drug-resistant and multidrug resistant Gram-negative bacteria. The usage and dosage of polymyxin B sulfate for injection were in line with the requirements of the drug instructions. The average duration of medication was( 11. 75 ± 8. 81) d. Most of the drug combination were carbapenems. Due to the reatment course of polymycin B sulfate for injection in two patients was less than 2 d
the efficacy was evaluated in 49 patients
and the anti-infective efficiency was 30. 61%( 15/49). Among 51 patients with polymyxin B sulfate for injection
22 cases had acute kidney injury( 43. 14%)
and 2 cases had skin pigmentation( 3. 92%). CONCLUSIONS: The clinical application of polymyxin B sulfate for injection still needs to be strictly managed
and adverse drug reactions such as nephrotoxicity and skin pigmentation should be concerned.